Medtech group Medacta readies Swiss IPO next year: sources By Reuters

0
351
© Reuters.  Medtech group Medacta readies Swiss IPO next year: sources


© Reuters. Medtech group Medacta readies Swiss IPO next year: sources

ZURICH/FRANKFURT (Reuters) – Swiss medical technology company Medacta is preparing to float on the SIX Swiss Exchange in spring next year, three people familiar with the matter told Reuters.

Credit Suisse (SIX:) and Morgan Stanley (NYSE:) are leading the deal with the help of JP Morgan and UBS, the sources said.

The company was not immediately available for comment and the banks all declined comment.

Family-owned Medacta generates annual sales of around 300 million Swiss francs, one of the people said. The company based in the Italian-speaking canton of Ticino will likely float just a minority stake at first.

Medacta, which employs 930 people, develops and manufactures orthopedic implants for knees and spines. Another Swiss implant group, Basel-based Medartis, was valued at 563 million Swiss francs when it went public in March.

Medacta’s higher profitability should give it a significantly higher market capitalization, the sources said.

Swiss trainmaker Stadler is also in the starting blocks for a Swiss listing next year.

The Swiss market for flotations is likely to slow next year after 10 new listings so far in 2018, of which six were initial public offerings (IPOs).

“IPOs only work now for companies with crisis-proof business models,” one source said, noting investors had become much more selective given market fluctuations.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here